Look Towards A New Future

Sep 12, 2010

Trends in Generics Industry Ownership: Evaluating changing industry paradigms and emerging players now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry  Trends in Generics Industry Ownership: Evaluating changing industry paradigms and emerging playersMarket Research Report in its Store.
Report Summary
The generic drug market is growing strongly as health plan payers around the world continue to implement incentives for participants, pharmacists, doctors and others to use generic, rather than branded, medications. Facing rising patent expirations, pharmaceutical companies are diversifying into their own generics businesses, creating a vibrant market for generic drug company acquisitions as they seek to capture market share. At the same time, startups and other generic drug companies are attempting to expand, seeking capital through private investments, public offerings and other means; and government-run companies in China, Latin America and other regions are privatizing.
This is creating a vibrant environment of many different ownership structures, only some of which are well suited to the companies for which they are utilized. This report examines these ownership structures in the context of current and future industry trends, discussing current best practices through nine case studies and examining which ownership structures are most effective for which types of situations.
Key features of this report
Identifies and analyses the most recent trends and issues in generic drug company ownership
Describes where different ownership structures are most appropriate and useful
Explores the complexities of key ownership structures in different world regions
Profiles the major generic drug companies and their ownership structures
Provides a detailed assessment of the current generic drug market including market share information and the size/growth forecasts
Discusses how the evolving biosimilars market will impact the industry and ownership structures
Scope of this report
Save time and money in research with the report’s up to date review and analysis of all the important trends in generic drug company ownership.
Develop deeper insight into the size and growth of the generic drug industry by utilising the report’s unique market forecasts.
Assess your organisation’s generic company ownership strategy by comparing it with those analyzed in the report’s 9 case studies.
Identify the differences between different ownership structures and which best fit the needs of your organisation.
Anticipate future generic drug company ownership trends and make your decisions as effective and economical as possible by understanding the current and future industry dynamics.
Key Market Issues
Patent expirations
Drug makers are facing continued patent expirations of leading products, causing many to enter the generics industry themselves as a means to diversify their operations.
Growth of generic drug usage
Around the world, generic drug usage is rising strongly as health care payers implement incentives for plan participants, pharmacists and physicians to use low cost generics rather than expensive branded drugs.
Rising acquisitions of generic drug companies
Acquisitions of generic drug companies, particularly by Big Pharma generic divisions, are strong and rising as a means for companies to both increase revenues and achieve economies of scale.
Increasing cross border deals
Acquirers are increasingly purchasing companies located in India, Africa and other offshore locations as the industry consolidates; this is creating more complicated ownership structures and management challenges.
Strong offshore investment climate
In the strong economies of India and China, generic drug companies are finding increased opportunities to raise expansion capital, leading to a higher number of publicly traded companies and companies with large minority or even majority shareholders.
Key findings from this report
Total generic drug sales reached $95b in 2009 and will expand by 7.2% per year through 2014. The Big Pharma segment is expanding most rapidly at 11.6% per year, followed by offshore generic drug companies at 9.4% per year and emerging generic drug makers at 3.4% per year.
Most generic drug companies are privately held, but ownership structure varies with market segment.
In the offshore region, more than one in seven generic drug makers is government owned but increased privatization is expected to provide acquisition opportunities to potential acquirers over the next few years.
Relatively few emerging generic drug companies are publicly traded; tight capital markets combined with Big Pharma’s preference for larger acquisitions will result in increased numbers of these companies being privately held and thereby having difficulty accessing expansion capital.
Most Big Pharma generic drug companies are wholly-owned subsidiaries; as new acquisitions are made, they tend to be folded into existing generic subsidiaries.
Key questions answered
What will the size and growth of the total generic, offshore generic, emerging generic and Big Pharma generic markets be through 2014?
Which companies are current and future key players?
What kind of ownership structures will offshore generic, emerging generic and Big Pharma generic companies establish in the future?
What are the benefits of each ownership structure for each type of generic drug company?
What role will acquisitions play in ownership structure?
Which ownership structures will be most effected by current economic and industry trends?
How is investment in each ownership structure made?
Table of Contents
Executive Summary 10
Overview of the generic drug industry 10
Offshore drug makers 11
Emerging generic drug makers 12
Big Pharma generic drug divisions 13
Future generic drug industry ownership trends 14
Chapter 1 Overview of the generic drug industry 15
Summary 15
Introduction 16
Current industry trends 16
Expiring patents on blockbusters 16
Healthcare cost containment 18
Low cost generics 19
Shift towards large molecules 19
The rise of generics 21
United States 22
Europe 23
Global sales of generic drugs, 2009 – 2014 25
Generic drug sales by therapeutic area, 2009-2014 25
Sales of generics by region, 2009-2014 27
United States 27
Europe 28
Generic drug sales by leading company 2009-2014 29
Generic drug sales by market segment, 2009-2014 30
Factors affecting generic drug sales and growth 31
Health and wellness trends 31
Economic trends 32
United States 33
Europe 34
US healthcare reform 35
Biosimilars 36
Generic manufacturer ownership structures 39
Government ownership 39
Private ownership 40
Public ownership 40
Subsidiary ownership 41
Joint ventures 42
Acquisitions 43
Case study: Mylan 44
Conclusion 45
Chapter 2 Offshore generic drug manufacturers 46
Summary 46
Introduction 47
The Indian generics industry 48
The Chinese generics market 49
The Japanese generics industry 52
Other offshore generic drug markets 53
Growth of generic drug sales from offshore players 55
Offshore companies’ generic drug sales as a proportion of total, 2009 – 2014 55
Factors affecting sales growth 56
Economic factors 56
Regulatory factors 57
Mergers and acquisitions 58
Ownership trends 60
Current ownership models 60
Key differentiators between ownership types 61
Management of companies by ownership type 64
Important recent changes of ownership 66
How investment is made 70
Startups vs. consolidation 72
Best practices 73
Implications for stakeholders 74
Generic drug companies 74
Offshore generic drug company investors 75
Conclusion 75
Chapter 3 Emerging generic drug makers 76
Summary 76
Introduction 77
New market entrants 78
Niche players 78
Biosimilar specialists 78
Therapeutic area specialists 82
Growth of generic drug sales from emerging players 82
Emerging companies’ generic drug sales as a proportion of total, 2009 – 2014 82
Factors affecting sales and growth 83
Economic factors 83
Regulatory factors 84
Mergers and acquisitions 84
Ownership trends 85
Current ownership types 85
Key differentiators among ownership types 85
Management of companies by ownership type 87
Important recent changes in ownership 87
How investment is made 88
Startups versus consolidation 90
Best practices 90
Implications for stakeholders 91
Generic drug companies 91
Emerging generic drug company investors 92
Conclusion 92Chapter 4 Big Pharma generic drug divisions 93
Summary 93
Introduction 94
Why Big Pharma entered the generic space 95
Key players 96
Case study: Novartis 96
Case study: Pfizer 98
Case study: Sanofi Aventis 99
Growth of generic drug sales from Big Pharma players 100
Big Pharma generic drug sales as a proportion of total, 2009 – 2014 100
Factors affecting sales growth 101
Economic factors 101
Industry challenges 102
Mergers and acquisitions 103
Current ownership types 105
Key differentiators among ownership types 105
Management of companies by ownership type 107
Important recent changes in ownership 108
How investment is made 109
Startup versus consolidation 109
Best practices 110
Implications for stakeholders 111
Big Pharma generic drug companies 111
Big Pharma generic drug company investors 111
Conclusion 112
Chapter 5 Future generic drug industry ownership trends 113
Summary 113
Introduction 114
The near term: 2010 – 2012 114
Ownership trends by type of player 115
Offshore generic drug makers 115
Emerging generic drug makers 116
Big Pharma generic drug makers 117
Implications for stakeholders 117
Offshore generic drug companies 117
Emerging generic drug companies 118
Big Pharma generic drug companies 118
The long term: 2013 – 2015 119
Ownership trends by type of player 120
Offshore generic drug makers 120
Emerging generic drug makers 121
Big Pharma generic drug makers 122
Implications for stakeholders 123
Offshore generic drug makers 123
Emerging generic drug makers 123
Big Pharma generic drug makers 124
Conclusion 124
Browse all Latest Report
Related Reports:
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004